| Literature DB >> 28404678 |
Melissa R Gitman1, Lisa McTaggart2, Joanna Spinato2, Rahgavi Poopalarajah2, Erin Lister2, Shahid Husain1,3, Julianne V Kus4,5.
Abstract
Aspergillus spp. cause serious invasive lung infections, and Aspergillus fumigatus is the most commonly encountered clinically significant species. Voriconazole is considered to be the drug of choice for treating A. fumigatus infections; however, rising resistance rates have been reported. We evaluated a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS)-based method for the differentiation between wild-type and non-wild-type isolates of 20 Aspergillus spp. (including 2 isolates of Aspergillus ustus and 1 of Aspergillus calidoustus that were used as controls due their intrinsic low azole susceptibility with respect to the in vitro response to voriconazole). At 30 and 48 h of incubation, there was complete agreement between Cyp51A sequence analysis, broth microdilution, and MALDI-TOF MS classification of isolates as wild type or non-wild type. In this proof-of-concept study, we demonstrated that MALDI-TOF MS can be used to accurately detect A. fumigatus strains with reduced voriconazole susceptibility. However, rather than proving to be a rapid and simple method for antifungal susceptibility testing, this particular MS-based method showed no benefit over conventional testing methods. © Crown copyright 2017.Entities:
Keywords: Aspergillus; MALDI-TOF MS; antifungal susceptibility testing; composite correlation index; voriconazole; voriconazole resistance
Mesh:
Substances:
Year: 2017 PMID: 28404678 PMCID: PMC5483904 DOI: 10.1128/JCM.00254-17
Source DB: PubMed Journal: J Clin Microbiol ISSN: 0095-1137 Impact factor: 5.948